|
Antibiotics
|
Susceptibility rate %
|
ESBL (n = 29)
|
Non-ESBL (n = 55)
|
p-value*
|
|---|
|
R
|
S
| | | |
|---|
|
AM
|
97.6
|
2.4
|
29 (100%)
|
50 (91 %)
|
0.4
|
|
AMC
|
85.7
|
14.3
|
24 (82.7%)
|
15 (27.3%)
|
10−4
|
|
AMX
|
95.2
|
4.8
|
29 (100%)
|
49 (89.1%)
|
0.17
|
|
IPM
|
3.6
|
96.4
|
01 (3.4%)
|
00 (0%)
|
0.3
|
|
CTX
|
56.5
|
40.5
|
28 (96.5%)
|
01 (1.8%)
|
<10−9
|
|
CRO
|
44.7
|
58.3
|
28 (96.5%)
|
01 (1.8%)
|
10−3
|
|
CIP
|
91.7
|
8.3
|
29 (100%)
|
14 (25.5%)
|
10−10
|
|
NOR
|
53.6
|
46.4
|
28 (96.5%)
|
14 (25.5%)
|
<10−9
|
|
AN
|
83.3
|
16.7
|
21(72.4%)
|
19 (34.5%)
|
0.04
|
|
G
|
45.2
|
54.8
|
24 (82.7)
|
12 (21.8)
|
10−7
|
|
SXT
|
86.9
|
13.1
|
29 (100%)
|
43 (78.2%)
|
6.10−3
|
- *P value is for the comparison of resistance of ESBL-producers with non-producers.
- AM: Ampicilline; AMC: Amoxicilline/clavulanic acid; AMX: Amoxicilline; IPM: Imipenem; CTX: Cefotaxime; CRO: Ceftriaxone; CIP: Ciprofloxacine; NOR: Norfloxacine; AN: Amikacine; G: Gentamicine; SXT: Trimethoprim/Sulfamethoxazole.
